



British Pharmacopoeia

British Pharmacopoeia Commission Secretariat

MHRA, 10 South Colonnade
Canary Wharf, London
E14 4PU, United Kingdom
pharmacopoeia.com

Date: 10 October 2022

TO WHOM IT MAY CONCERN

RIFAXIMIN TABLETS BP 2023

It has come to our attention that in the Dissolution test, Solution A should be adjusted to pH 5.0 with glacial acetic acid and that the test and standard solutions should be diluted to a concentration of 0.003% w/v of Rifaximin. The monograph will therefore be revised to reflect these changes in a future publication.

Please accept this as a notice of intent to amend the monograph on behalf of the British Pharmacopoeia Commission. This letter is for information only and does not represent a legally-enforceable standard. The revised monograph will be published in a future edition of the British Pharmacopoeia - the current target publication is the BP 2024, which will come into force on 1st January 2024.

If you have any questions concerning this letter, please do not hesitate to contact the British Pharmacopoeia Secretariat (BPCOM@mhra.gov.uk).

Yours faithfully,

MR JAMES POUND

Secretary & Scientific Director

Email: BPCOM@mhra.gov.uk